Results 81 to 90 of about 20,646 (210)

Real‐world progression‐free survival and overall survival in patients with HR+/HER2− advanced breast cancer treated in first‐line with ribociclib, endocrine monotherapy or chemotherapy: Results from the observational RIBANNA study

International Journal of Cancer, Volume 159, Issue 1, Page 210-223, 1 July 2026.
What's New? The CDK4/6 inhibitor ribociclib in combination with an endocrine‐based therapy has demonstrated significant progression‐free and overall survival benefits in patients with advanced/metastatic HR+/HER2‐ breast cancer in the pivotal MONALEESA trials.
Peter A. Fasching, Cosima Brucker, Thomas Decker, Anne Engel, Thomas Göhler, Christian Jackisch, Jan Janssen, Andreas Köhler, Kerstin Lüdtke‐Heckenkamp, Diana Lüftner, Frederik Marmé, Marion van Mackelenbergh, Beate Rautenberg, Marcus Schmidt, Rudolf Weide, Pauline Wimberger, Elena Kisseleff, Christina Pfister, Claudia Quiering, Christian Roos, Achim Wöckel   +20 more
wiley   +1 more source

A comparison of letrozole and anastrozole followed by letrozole in breast cancer patients

, 2015
Potchavit Aphinives, Damnern Vachirodom, Chaiyut Thanapaisal, Dhanes Rangsrikajee, Ongart SomintaraDepartment of Surgery, Faculty of Medicine, Khon Kaen University, Khon Kaen, ThailandBackground: We previously studied the noninferiority of anastrozole ...
Thanapaisal C, Rangsrikajee D, Somintara O, Vachirodom D, Aphinives P   +4 more
core  

Age, Age‐Related Comorbidities and Survival in Palbociclib, Ribociclib and Abemaciclib Users With Advanced Breast Cancer: A Nation‐Wide Retrospective Cohort Study

Pharmacoepidemiology and Drug Safety, Volume 35, Issue 7, July 2026.
ABSTRACT Purpose Prevalence of breast cancer (BC) increases with age, but the external validity of data obtained from pivotal trials of medicinal products remains a concern due to the underrepresentation of frail and older adults. Cyclin‐dependent kinase inhibitors (CDKi), palbociclib, abemaciclib, and ribociclib are considered an essential part of the
Blair Rajamaki, Olli Tenhunen, Liisa Pylkkänen, Thuan Vo, Anne Paakinaho, Miia Turpeinen, Sirpa Hartikainen, Anna‐Maija Tolppanen   +7 more
wiley   +1 more source

Diagnostic Impact of Liver Biopsy Among Antinuclear Antibody Positive Individuals With Mild Liver Enzyme Elevation

Alimentary Pharmacology &Therapeutics, Volume 64, Issue 1, Page 103-111, July 2026.
In ANA‐positive patients with suspected autoimmune hepatitis (AIH), liver biopsy rarely altered therapeutic management when alanine aminotransferase (ALT) was below 101 U/L and cirrhosis was absent. These findings suggest that biopsy may be safely deferred in this low‐risk group.
David Mehdi Asgher Niazi, Alphonse Charbel, Jan Pfeiffenberger, Uta Merle, Jessica Seessle, Theresa Wenz, Christa Flechtenmacher, Patrick Michl, Conrad Rauber   +8 more
wiley   +1 more source

From Multiple Congenital Anomalies to Pituitary Gland Malformation: Wide Spectrum of Clinical Features in a Family With FOXA2 Variant

American Journal of Medical Genetics Part A, Volume 200, Issue 6, Page 1452-1457, June 2026.
ABSTRACT FOXA2 (hepatocyte nuclear factor‐3β, HNF‐3β) encodes a transcriptional activator involved in early embryogenesis, particularly in the patterning and differentiation of midline structures such as the neural tube, foregut, and pituitary gland. Its role in human pathogenesis was first suspected when patients with deletion of chromosome 20p11.2 ...
Christopher Connolly, Hemant A. Parmar, Lauren Hipp, Tomoyasu Higashimoto   +3 more
wiley   +1 more source

Dried blood spot analysis in antidoping: Technical challenges, analytical advances, and future perspectives

Bulletin of the Korean Chemical Society, Volume 47, Issue 6, Page 674-688, June 2026.
Dried blood spot (DBS) analysis enables minimally invasive blood collection with strong analyte stability and simplified logistics, supporting anti‐doping applications beyond traditional matrices. Recent advances address hematocrit, volume variability, and matrix effects while expanding coverage to steroid esters, World Anti‐Doping Agency‐listed ...
Jihyun Yoon, Jiyeong Hong, Hanbin Oh, Chi Hwan Lee, Ki Hun Kim   +4 more
wiley   +1 more source

Long-term efficacy and safety of letrozole for the adjuvant treatment of early breast cancer in postmenopausal women: a review

, 2009
Alain MonnierInstitut Régional Fédératif du Cancer (IFRC), Centre Hospitalier Belfort-Montbéliard, Montbéliard, FranceAbstract: Aromatase inhibitors (AIs) are becoming more widely used than tamoxifen
Alain Monnier
core  

Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.

, 2009
International audiencePURPOSE: Cross-talk between human epidermal growth factor receptors and hormone receptor pathways may cause endocrine resistance in breast cancer. This trial evaluated the effect of adding lapatinib, a dual tyrosine kinase inhibitor
Mark Pegram, Steven Stein, Pippen, John, Cristina Oliva, Press, Michael, F., Gilles Romieu, Alexey Manikhas, Lisa O'Rourke, Pivot, Xavier, B., Veronique Dieras, Stein, Steven, Pegram, Mark, Dieras, Veronique, O'Rourke, Lisa, Maltzman, Julie, John Pippen, Xavier Pivot, Allison Florance, Romieu, Gilles, Oliva, Cristina, M. John Kennedy, Kennedy, M John, Sadeghi, Saeed, Florance, Allison, Manikhas, Alexey, Henry Leonidas Gomez, Saeed Sadeghi, Stephen Johnston, Johnston, Stephen, Lichinitser, Mikhail, Gomez, Henry Leonidas, Mikhail Lichinitser, Julie Maltzman, Michael F. Press   +33 more
core   +1 more source

Rationale and Trial Design of DAWNA‐FES Trial: Single‐Arm Phase II Study of Endocrine Therapy With Dalpiciclib After Progression on CDK4/6 Inhibition Based on [18F]FES PET/CT in Patients With HR+/HER2− Advanced Breast Cancer

Cancer Innovation, Volume 5, Issue 3, June 2026.
The DAWNA‐FES trial is a prospective, single‐center, single‐arm phase II study evaluating dalpiciclib plus endocrine therapy in patients with HR+/HER2− advanced breast cancer who have progressed on prior CDK4/6 inhibitors and have at least one [18F]FES‐positive lesion.
Ru Yao, Yang Qu, Zhixin Hao, Ying Xu, Jiahui Zhang, Jie Lian, Lu Gao, Songjie Shen, Feng Mao, Bo Pan, Qiang Sun, Li Huo, Yidong Zhou   +12 more
wiley   +1 more source

Use of letrozole and clomiphene citrate combined with gonadotropins in clomiphene-resistant infertile women with polycystic ovary syndrome: a prospective study

, 2015
Wenyan Xi,1 Shankun Liu,2 Hui Mao,1 Yongkang Yang,1 Xiang Xue,1 Xiaoning Lu1 1The Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an City, Shaanxi, 2Taian City Central Hospital, Shandong, Taian, People’s Republic of  ...
Xi W, Yang Y, Lu X, Mao H, Liu S, Xue X
core